Company / Named in our posts
BridgeBio Oncology Therapeutics.
Follow BridgeBio Oncology TherapeuticsA clinical-stage biopharmaceutical company advancing a pipeline of small molecule therapeutics targeting RAS and PI3K malignancies.[1]
01Deal
Deals on Carrywatch
Every deal that names BridgeBio Oncology Therapeutics, and its role in each.
Helix Acquisition Corp. / BridgeBio Oncology Therapeutics
Helix Acquisition Corp. and BridgeBio Oncology Therapeutics complete business combination
See deal detailsDeal Web
BridgeBio Oncology Therapeutics and 0 firms it shares a posted deal with, and the path to any other firm.
Financials
2 fiscal years of figures as BridgeBio Oncology Therapeutics reported them.
News
Loading headlines.
Sources
As of 25 Oct 2026.
- 01The Unaudited Condensed Consolidated Financial Statements of BBOT as of June 30, 2025
U.S. Securities and Exchange Commission · Researched 25 Oct 2026
Deal posts naming BridgeBio Oncology Therapeutics:
- P01